{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T01:59:52Z","timestamp":1793930392663,"version":"4.8.0"},"reference-count":219,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2023,9,21]],"date-time":"2023-09-21T00:00:00Z","timestamp":1695254400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,9,21]],"date-time":"2023-09-21T00:00:00Z","timestamp":1695254400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Nephrol"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1038\/s41581-023-00766-1","type":"journal-article","created":{"date-parts":[[2023,9,21]],"date-time":"2023-09-21T15:03:14Z","timestamp":1695308594000},"page":"771-787","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":117,"title":["The role of complement in kidney disease"],"prefix":"10.1038","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6024-0562","authenticated-orcid":false,"given":"Vojtech","family":"Petr","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3476-9956","authenticated-orcid":false,"given":"Joshua M.","family":"Thurman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,9,21]]},"reference":[{"key":"766_CR1","unstructured":"Ehrlich, P. Collected Studies on Immunity (John Wiley & Sons, 1906)."},{"key":"766_CR2","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1111\/j.1523-1755.2005.67109.x","volume":"67","author":"JM Thurman","year":"2005","unstructured":"Thurman, J. M., Lucia, M. S., Ljubanovic, D. & Holers, V. M. Acute tubular necrosis is characterized by activation of the alternative pathway of complement. Kidney Int. 67, 524\u2013530 (2005).","journal-title":"Kidney Int."},{"key":"766_CR3","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1681\/ASN.V102281","volume":"10","author":"M Noris","year":"1999","unstructured":"Noris, M. et al. Hypocomplementemia discloses genetic predisposition to hemolytic uremic syndrome and thrombotic thrombocytopenic purpura: role of factor H abnormalities. Italian Registry of Familial and Recurrent Hemolytic Uremic Syndrome\/Thrombotic Thrombocytopenic Purpura. J. Am. Soc. Nephrol. 10, 281\u2013293 (1999).","journal-title":"J. Am. Soc. Nephrol."},{"key":"766_CR4","doi-asserted-by":"publisher","first-page":"2318","DOI":"10.1111\/ajt.15898","volume":"20","author":"A Loupy","year":"2020","unstructured":"Loupy, A. et al. The Banff 2019 Kidney Meeting Report (I): updates on and clarification of criteria for T cell- and antibody-mediated rejection. Am. J. Transplant. 20, 2318\u20132331 (2020).","journal-title":"Am. J. Transplant."},{"key":"766_CR5","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/s41577-019-0168-x","volume":"19","author":"ES Reis","year":"2019","unstructured":"Reis, E. S., Mastellos, D. C., Hajishengallis, G. & Lambris, J. D. New insights into the immune functions of complement. Nat. Rev. Immunol. 19, 503\u2013516 (2019).","journal-title":"Nat. Rev. Immunol."},{"key":"766_CR6","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1146\/annurev-neuro-061010-113810","volume":"35","author":"AH Stephan","year":"2012","unstructured":"Stephan, A. H., Barres, B. A. & Stevens, B. The complement system: an unexpected role in synaptic pruning during development and disease. Annu. Rev. Neurosci. 35, 369\u2013389 (2012).","journal-title":"Annu. Rev. Neurosci."},{"key":"766_CR7","doi-asserted-by":"publisher","first-page":"aad1210","DOI":"10.1126\/science.aad1210","volume":"352","author":"G Arbore","year":"2016","unstructured":"Arbore, G. et al. T helper 1 immunity requires complement-driven NLRP3 inflammasome activity in CD4+ T cells. Science 352, aad1210 (2016).","journal-title":"Science"},{"key":"766_CR8","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1182\/blood-2006-12-063636","volume":"110","author":"X Zhang","year":"2007","unstructured":"Zhang, X. et al. Regulation of Toll-like receptor-mediated inflammatory response by complement in vivo. Blood 110, 228\u2013236 (2007).","journal-title":"Blood"},{"key":"766_CR9","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1038\/nm1419","volume":"12","author":"M Huber-Lang","year":"2006","unstructured":"Huber-Lang, M. et al. Generation of C5a in the absence of C3: a new complement activation pathway. Nat. Med. 12, 682\u2013687 (2006).","journal-title":"Nat. Med."},{"key":"766_CR10","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1111\/imr.13136","volume":"313","author":"VM Holers","year":"2023","unstructured":"Holers, V. M. Contributions of animal models to mechanistic understandings of antibody-dependent disease and roles of the amplification loop. Immunol. Rev. 313, 181\u2013193 (2023).","journal-title":"Immunol. Rev."},{"key":"766_CR11","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.molimm.2015.03.011","volume":"67","author":"RB Pouw","year":"2015","unstructured":"Pouw, R. B., Vredevoogd, D. W., Kuijpers, T. W. & Wouters, D. Of mice and men: the factor H protein family and complement regulation. Mol. Immunol. 67, 12\u201320 (2015).","journal-title":"Mol. Immunol."},{"key":"766_CR12","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/0161-5890(95)00135-2","volume":"33","author":"RO Ebanks","year":"1996","unstructured":"Ebanks, R. O. & Isenman, D. E. Mouse complement component C4 is devoid of classical pathway C5 convertase subunit activity. Mol. Immunol. 33, 297\u2013309 (1996).","journal-title":"Mol. Immunol."},{"key":"766_CR13","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1172\/JCI115314","volume":"88","author":"RA Brooimans","year":"1991","unstructured":"Brooimans, R. A. et al. Interleukin 2 mediates stimulation of complement C3 biosynthesis in human proximal tubular epithelial cells. J. Clin. Invest. 88, 379\u2013384 (1991).","journal-title":"J. Clin. Invest."},{"key":"766_CR14","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1038\/ki.1996.344","volume":"50","author":"TR Welch","year":"1996","unstructured":"Welch, T. R., Beischel, L. S., Frenzke, M. & Witte, D. Regulated expression of complement factor B in the human kidney. Kidney Int. 50, 521\u2013525 (1996).","journal-title":"Kidney Int."},{"key":"766_CR15","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1038\/ki.1989.302","volume":"36","author":"J Zwirner","year":"1989","unstructured":"Zwirner, J., Felber, E., Herzog, V., Riethmuller, G. & Feucht, H. E. Classical pathway of complement activation in normal and diseased human glomeruli. Kidney Int. 36, 1069\u20131077 (1989).","journal-title":"Kidney Int."},{"key":"766_CR16","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.imbio.2006.11.009","volume":"212","author":"AW Dodds","year":"2007","unstructured":"Dodds, A. W. & Matsushita, M. The phylogeny of the complement system and the origins of the classical pathway. Immunobiology 212, 233\u2013243 (2007).","journal-title":"Immunobiology"},{"key":"766_CR17","doi-asserted-by":"publisher","first-page":"10127","DOI":"10.1073\/pnas.0402180101","volume":"101","author":"M Matsushita","year":"2004","unstructured":"Matsushita, M. et al. Origin of the classical complement pathway: Lamprey orthologue of mammalian C1q acts as a lectin. Proc. Natl Acad. Sci. USA 101, 10127\u201310131 (2004).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"766_CR18","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1111\/imr.12468","volume":"274","author":"P Garred","year":"2016","unstructured":"Garred, P. et al. A journey through the lectin pathway of complement-MBL and beyond. Immunol. Rev. 274, 74\u201397 (2016).","journal-title":"Immunol. Rev."},{"key":"766_CR19","doi-asserted-by":"publisher","first-page":"1724","DOI":"10.1681\/ASN.2005090923","volume":"17","author":"A Roos","year":"2006","unstructured":"Roos, A. et al. Glomerular activation of the lectin pathway of complement in IgA nephropathy is associated with more severe renal disease. J. Am. Soc. Nephrol. 17, 1724\u20131734 (2006).","journal-title":"J. Am. Soc. Nephrol."},{"key":"766_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-36068-0","volume":"14","author":"L Seifert","year":"2023","unstructured":"Seifert, L. et al. The classical pathway triggers pathogenic complement activation in membranous nephropathy. Nat. Commun. 14, 473 (2023).","journal-title":"Nat. Commun."},{"key":"766_CR21","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1111\/j.1365-2249.2004.02627.x","volume":"138","author":"M Harboe","year":"2004","unstructured":"Harboe, M., Ulvund, G., Vien, L., Fung, M. & Mollnes, T. E. The quantitative role of alternative pathway amplification in classical pathway induced terminal complement activation. Clin. Exp. Immunol. 138, 439\u2013446 (2004).","journal-title":"Clin. Exp. Immunol."},{"key":"766_CR22","doi-asserted-by":"publisher","DOI":"10.1002\/cti2.1436","volume":"12","author":"EC de Boer","year":"2023","unstructured":"de Boer, E. C. et al. The contribution of the alternative pathway in complement activation on cell surfaces depends on the strength of classical pathway initiation. Clin. Transl. Immunol. 12, e1436 (2023).","journal-title":"Clin. Transl. Immunol."},{"key":"766_CR23","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1096\/fj.201700734","volume":"32","author":"PJ Lachmann","year":"2018","unstructured":"Lachmann, P. J., Lay, E. & Seilly, D. J. Experimental confirmation of the C3 tickover hypothesis by studies with an Ab (S77) that inhibits tickover in whole serum. FASEB J. 32, 123\u2013129 (2018).","journal-title":"FASEB J."},{"key":"766_CR24","first-page":"254","volume":"56","author":"D Jean","year":"1996","unstructured":"Jean, D. et al. A cysteine proteinase, which cleaves human C3, the third component of complement, is involved in tumorigenicity and metastasis of human melanoma. Cancer Res. 56, 254\u2013258 (1996).","journal-title":"Cancer Res."},{"key":"766_CR25","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1056\/NEJM198502143120702","volume":"312","author":"JE Volanakis","year":"1985","unstructured":"Volanakis, J. E., Barnum, S. R., Giddens, M. & Galla, J. H. Renal filtration and catabolism of complement protein D. N. Engl. J. Med. 312, 395\u2013399 (1985).","journal-title":"N. Engl. J. Med."},{"key":"766_CR26","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.135758","author":"Y Zhang","year":"2020","unstructured":"Zhang, Y. et al. C3(H2O) prevents rescue of complement-mediated C3 glomerulopathy in Cfh\u2212\/\u2212 Cfd\u2212\/\u2212 mice. JCI Insight https:\/\/doi.org\/10.1172\/jci.insight.135758 (2020).","journal-title":"JCI Insight"},{"key":"766_CR27","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.117.007818","author":"D Jalal","year":"2018","unstructured":"Jalal, D. et al. Endothelial microparticles and systemic complement activation in patients with chronic kidney disease. J. Am. Heart Assoc. https:\/\/doi.org\/10.1161\/JAHA.117.007818 (2018).","journal-title":"J. Am. Heart Assoc."},{"key":"766_CR28","doi-asserted-by":"publisher","first-page":"262","DOI":"10.3389\/fimmu.2015.00262","volume":"6","author":"NS Merle","year":"2015","unstructured":"Merle, N. S., Church, S. E., Fremeaux-Bacchi, V. & Roumenina, L. T. Complement system part I \u2014 molecular mechanisms of activation and regulation. Front. Immunol. 6, 262 (2015).","journal-title":"Front. Immunol."},{"key":"766_CR29","doi-asserted-by":"publisher","first-page":"2014","DOI":"10.1056\/NEJMoa052825","volume":"354","author":"KM Brown","year":"2006","unstructured":"Brown, K. M. et al. Influence of donor C3 allotype on late renal-transplantation outcome. N. Engl. J. Med. 354, 2014\u20132023 (2006).","journal-title":"N. Engl. J. Med."},{"key":"766_CR30","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1038\/nm0602-582","volume":"8","author":"JR Pratt","year":"2002","unstructured":"Pratt, J. R., Basheer, S. A. & Sacks, S. H. Local synthesis of complement component C3 regulates acute renal transplant rejection. Nat. Med. 8, 582\u2013587 (2002).","journal-title":"Nat. Med."},{"key":"766_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-10861-2","volume":"10","author":"BB Lake","year":"2019","unstructured":"Lake, B. B. et al. A single-nucleus RNA-sequencing pipeline to decipher the molecular anatomy and pathophysiology of human kidneys. Nat. Commun. 10, 2832 (2019).","journal-title":"Nat. Commun."},{"key":"766_CR32","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.1016\/j.ajpath.2018.06.018","volume":"188","author":"M Sircar","year":"2018","unstructured":"Sircar, M. et al. Complement 7 is up-regulated in human early diabetic kidney disease. Am. J. Pathol. 188, 2147\u20132154 (2018).","journal-title":"Am. J. Pathol."},{"key":"766_CR33","doi-asserted-by":"publisher","first-page":"4336","DOI":"10.4049\/jimmunol.162.7.4336","volume":"162","author":"S Tang","year":"1999","unstructured":"Tang, S., Zhou, W., Sheerin, N. S., Vaughan, R. W. & Sacks, S. H. Contribution of renal secreted complement C3 to the circulating pool in humans. J. Immunol. 162, 4336\u20134341 (1999).","journal-title":"J. Immunol."},{"key":"766_CR34","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1038\/s41581-023-00704-1","volume":"19","author":"EE West","year":"2023","unstructured":"West, E. E. & Kemper, C. Complosome \u2014 the intracellular complement system. Nat. Rev. Nephrol. 19, 426\u2013439 (2023).","journal-title":"Nat. Rev. Nephrol."},{"key":"766_CR35","doi-asserted-by":"publisher","first-page":"624025","DOI":"10.3389\/fcell.2021.624025","volume":"9","author":"S Vandendriessche","year":"2021","unstructured":"Vandendriessche, S., Cambier, S., Proost, P. & Marques, P. E. Complement receptors and their role in leukocyte recruitment and phagocytosis. Front. Cell. Dev. Biol. 9, 624025 (2021).","journal-title":"Front. Cell. Dev. Biol."},{"key":"766_CR36","doi-asserted-by":"publisher","DOI":"10.1172\/JCI162253","author":"A Stokowska","year":"2023","unstructured":"Stokowska, A. et al. Complement C3a treatment accelerates recovery after stroke via modulation of astrocyte reactivity and cortical connectivity. J. Clin. Invest. https:\/\/doi.org\/10.1172\/JCI162253 (2023).","journal-title":"J. Clin. Invest."},{"key":"766_CR37","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1084\/jem.20030374","volume":"198","author":"CW Strey","year":"2003","unstructured":"Strey, C. W. et al. The proinflammatory mediators C3a and C5a are essential for liver regeneration. J. Exp. Med. 198, 913\u2013923 (2003).","journal-title":"J. Exp. Med."},{"key":"766_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms10587","volume":"7","author":"M Serna","year":"2016","unstructured":"Serna, M., Giles, J. L., Morgan, B. P. & Bubeck, D. Structural basis of complement membrane attack complex formation. Nat. Commun. 7, 10587 (2016).","journal-title":"Nat. Commun."},{"key":"766_CR39","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1038\/nri2620","volume":"9","author":"PF Zipfel","year":"2009","unstructured":"Zipfel, P. F. & Skerka, C. Complement regulators and inhibitory proteins. Nat. Rev. Immunol. 9, 729\u2013740 (2009).","journal-title":"Nat. Rev. Immunol."},{"key":"766_CR40","doi-asserted-by":"publisher","first-page":"19237","DOI":"10.1074\/jbc.274.27.19237","volume":"274","author":"AM Blom","year":"1999","unstructured":"Blom, A. M., Webb, J., Villoutreix, B. O. & Dahlback, B. A cluster of positively charged amino acids in the C4BP \u03b1-chain is crucial for C4b binding and factor I cofactor function. J. Biol. Chem. 274, 19237\u201319245 (1999).","journal-title":"J. Biol. Chem."},{"key":"766_CR41","doi-asserted-by":"publisher","first-page":"7371","DOI":"10.4049\/jimmunol.0902388","volume":"183","author":"SE Degn","year":"2009","unstructured":"Degn, S. E. et al. MAp44, a human protein associated with pattern recognition molecules of the complement system and regulating the lectin pathway of complement activation. J. Immunol. 183, 7371\u20137378 (2009).","journal-title":"J. Immunol."},{"key":"766_CR42","doi-asserted-by":"publisher","first-page":"6533","DOI":"10.4049\/jimmunol.0804207","volume":"182","author":"SL Mueller-Ortiz","year":"2009","unstructured":"Mueller-Ortiz, S. L. et al. Targeted disruption of the gene encoding the murine small subunit of carboxypeptidase N (CPN1) causes susceptibility to C5a anaphylatoxin-mediated shock. J. Immunol. 182, 6533\u20136539 (2009).","journal-title":"J. Immunol."},{"key":"766_CR43","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1111\/imr.13166","volume":"313","author":"L Lucientes-Continente","year":"2023","unstructured":"Lucientes-Continente, L., Marquez-Tirado, B. & Goicoechea de Jorge, E. The factor H protein family: the switchers of the complement alternative pathway. Immunol. Rev. 313, 25\u201345 (2023).","journal-title":"Immunol. Rev."},{"key":"766_CR44","doi-asserted-by":"publisher","first-page":"2185","DOI":"10.1182\/blood.2021012037","volume":"138","author":"H Martin Merinero","year":"2021","unstructured":"Martin Merinero, H. et al. Functional characterization of 105 factor H variants associated with aHUS: lessons for variant classification. Blood 138, 2185\u20132201 (2021).","journal-title":"Blood"},{"key":"766_CR45","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1136\/jmg.2006.045328","volume":"44","author":"A Servais","year":"2007","unstructured":"Servais, A. et al. Primary glomerulonephritis with isolated C3 deposits: a new entity which shares common genetic risk factors with haemolytic uraemic syndrome. J. Med. Genet. 44, 193\u2013199 (2007).","journal-title":"J. Med. Genet."},{"key":"766_CR46","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1016\/j.ekir.2019.06.008","volume":"4","author":"NR Medjeral-Thomas","year":"2019","unstructured":"Medjeral-Thomas, N. R. et al. Glomerular complement factor H-related protein 5 (FHR5) is highly prevalent in C3 glomerulopathy and associated with renal impairment. Kidney Int. Rep. 4, 1387\u20131400 (2019).","journal-title":"Kidney Int. Rep."},{"key":"766_CR47","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1016\/j.kint.2017.03.043","volume":"92","author":"NR Medjeral-Thomas","year":"2017","unstructured":"Medjeral-Thomas, N. R. et al. Circulating complement factor H-related proteins 1 and 5 correlate with disease activity in IgA nephropathy. Kidney Int. 92, 942\u2013952 (2017).","journal-title":"Kidney Int."},{"key":"766_CR48","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.kint.2016.10.005","volume":"91","author":"TH Goodship","year":"2017","unstructured":"Goodship, T. H. et al. Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a \u201cKidney Disease: Improving Global Outcomes\u201d (KDIGO) Controversies Conference. Kidney Int. 91, 539\u2013551 (2017).","journal-title":"Kidney Int."},{"key":"766_CR49","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1056\/NEJMra0902814","volume":"361","author":"M Noris","year":"2009","unstructured":"Noris, M. & Remuzzi, G. Atypical hemolytic-uremic syndrome. N. Engl. J. Med. 361, 1676\u20131687 (2009).","journal-title":"N. Engl. J. Med."},{"key":"766_CR50","doi-asserted-by":"publisher","first-page":"369","DOI":"10.3109\/13816810.2015.1101777","volume":"37","author":"J Savige","year":"2016","unstructured":"Savige, J. et al. Retinal disease in the C3 glomerulopathies and the risk of impaired vision. Ophthalmic Genet. 37, 369\u2013376 (2016).","journal-title":"Ophthalmic Genet."},{"key":"766_CR51","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/nrneph.2016.99","volume":"12","author":"MA Durey","year":"2016","unstructured":"Durey, M. A., Sinha, A., Togarsimalemath, S. K. & Bagga, A. Anti-complement-factor H-associated glomerulopathies. Nat. Rev. Nephrol. 12, 563\u2013578 (2016).","journal-title":"Nat. Rev. Nephrol."},{"key":"766_CR52","doi-asserted-by":"publisher","first-page":"2329","DOI":"10.3389\/fimmu.2018.02329","volume":"9","author":"R Donadelli","year":"2018","unstructured":"Donadelli, R. et al. Unraveling the molecular mechanisms underlying complement dysregulation by nephritic factors in C3G and IC-MPGN. Front. Immunol. 9, 2329 (2018).","journal-title":"Front. Immunol."},{"key":"766_CR53","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1053\/j.ajkd.2010.06.021","volume":"56","author":"S Sethi","year":"2010","unstructured":"Sethi, S. et al. Dense deposit disease associated with monoclonal gammopathy of undetermined significance. Am. J. Kidney Dis. 56, 977\u2013982 (2010).","journal-title":"Am. J. Kidney Dis."},{"key":"766_CR54","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1016\/j.kint.2018.02.029","volume":"94","author":"F Schaefer","year":"2018","unstructured":"Schaefer, F. et al. Clinical and genetic predictors of atypical hemolytic uremic syndrome phenotype and outcome. Kidney Int. 94, 408\u2013418 (2018).","journal-title":"Kidney Int."},{"key":"766_CR55","doi-asserted-by":"publisher","first-page":"3528","DOI":"10.4049\/jimmunol.1200679","volume":"189","author":"C Blanc","year":"2012","unstructured":"Blanc, C. et al. Overall neutralization of complement factor H by autoantibodies in the acute phase of the autoimmune form of atypical hemolytic uremic syndrome. J. Immunol. 189, 3528\u20133537 (2012).","journal-title":"J. Immunol."},{"key":"766_CR56","doi-asserted-by":"publisher","first-page":"3702","DOI":"10.1172\/JCI43343","volume":"120","author":"R Martinez-Barricarte","year":"2010","unstructured":"Martinez-Barricarte, R. et al. Human C3 mutation reveals a mechanism of dense deposit disease pathogenesis and provides insights into complement activation and regulation. J. Clin. Invest. 120, 3702\u20133712 (2010).","journal-title":"J. Clin. Invest."},{"key":"766_CR57","doi-asserted-by":"publisher","first-page":"2464","DOI":"10.4049\/jimmunol.1701695","volume":"200","author":"AJ Osborne","year":"2018","unstructured":"Osborne, A. J. et al. Statistical validation of rare complement variants provides insights into the molecular basis of atypical hemolytic uremic syndrome and C3 glomerulopathy. J. Immunol. 200, 2464\u20132478 (2018).","journal-title":"J. Immunol."},{"key":"766_CR58","doi-asserted-by":"publisher","DOI":"10.1111\/imr.13168","author":"JM Thurman","year":"2022","unstructured":"Thurman, J. M. & Harrison, R. A. The susceptibility of the kidney to alternative pathway activation \u2014 a hypothesis. Immunol. Rev. https:\/\/doi.org\/10.1111\/imr.13168 (2022).","journal-title":"Immunol. Rev."},{"key":"766_CR59","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1016\/j.kint.2020.01.035","volume":"97","author":"E Rondeau","year":"2020","unstructured":"Rondeau, E. et al. The long-acting C5 inhibitor, ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naive to complement inhibitor treatment. Kidney Int. 97, 1287\u20131296 (2020).","journal-title":"Kidney Int."},{"key":"766_CR60","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1056\/NEJMoa1208981","volume":"368","author":"CM Legendre","year":"2013","unstructured":"Legendre, C. M. et al. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N. Engl. J. Med. 368, 2169\u20132181 (2013).","journal-title":"N. Engl. J. Med."},{"key":"766_CR61","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1053\/j.ajkd.2018.12.046","volume":"74","author":"P Ruggenenti","year":"2019","unstructured":"Ruggenenti, P. et al. C5 Convertase blockade in membranoproliferative glomerulonephritis: a single-arm clinical trial. Am. J. Kidney Dis. 74, 224\u2013238 (2019).","journal-title":"Am. J. Kidney Dis."},{"key":"766_CR62","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1111\/j.1523-1755.2004.00365.x","volume":"65","author":"SH Nasr","year":"2004","unstructured":"Nasr, S. H. et al. Proliferative glomerulonephritis with monoclonal IgG deposits: a distinct entity mimicking immune-complex glomerulonephritis. Kidney Int. 65, 85\u201396 (2004).","journal-title":"Kidney Int."},{"key":"766_CR63","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1681\/ASN.2009010110","volume":"20","author":"SH Nasr","year":"2009","unstructured":"Nasr, S. H. et al. Proliferative glomerulonephritis with monoclonal IgG deposits. J. Am. Soc. Nephrol. 20, 2055\u20132064 (2009).","journal-title":"J. Am. Soc. Nephrol."},{"key":"766_CR64","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1038\/sj.ki.5000123","volume":"69","author":"SH Nasr","year":"2006","unstructured":"Nasr, S. H. et al. Dysproteinemia, proteinuria, and glomerulonephritis. Kidney Int. 69, 772\u2013775 (2006).","journal-title":"Kidney Int."},{"key":"766_CR65","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.kint.2018.01.037","volume":"94","author":"A Ravindran","year":"2018","unstructured":"Ravindran, A., Fervenza, F. C., Smith, R. J. H. & Sethi, S. C3 glomerulopathy associated with monoclonal Ig is a distinct subtype. Kidney Int. 94, 178\u2013186 (2018).","journal-title":"Kidney Int."},{"key":"766_CR66","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1084\/jem.175.4.939","volume":"175","author":"S Meri","year":"1992","unstructured":"Meri, S., Koistinen, V., Miettinen, A., Tornroth, T. & Seppala, I. J. Activation of the alternative pathway of complement by monoclonal lambda light chains in membranoproliferative glomerulonephritis. J. Exp. Med. 175, 939\u2013950 (1992).","journal-title":"J. Exp. Med."},{"key":"766_CR67","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1038\/ki.2012.63","volume":"82","author":"A Servais","year":"2012","unstructured":"Servais, A. et al. Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies. Kidney Int. 82, 454\u2013464 (2012).","journal-title":"Kidney Int."},{"key":"766_CR68","doi-asserted-by":"publisher","first-page":"2852","DOI":"10.1681\/ASN.2014040406","volume":"26","author":"S Sethi","year":"2015","unstructured":"Sethi, S., Nasr, S. H., De Vriese, A. S. & Fervenza, F. C. C4d as a diagnostic tool in proliferative GN. J. Am. Soc. Nephrol. 26, 2852\u20132859 (2015).","journal-title":"J. Am. Soc. Nephrol."},{"key":"766_CR69","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1038\/ki.2013.340","volume":"85","author":"J Hou","year":"2014","unstructured":"Hou, J. et al. Toward a working definition of C3 glomerulopathy by immunofluorescence. Kidney Int. 85, 450\u2013456 (2014).","journal-title":"Kidney Int."},{"key":"766_CR70","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.molimm.2016.01.010","volume":"71","author":"P Iatropoulos","year":"2016","unstructured":"Iatropoulos, P. et al. Complement gene variants determine the risk of immunoglobulin-associated MPGN and C3 glomerulopathy and predict long-term renal outcome. Mol. Immunol. 71, 131\u2013142 (2016).","journal-title":"Mol. Immunol."},{"key":"766_CR71","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1126\/science.1248943","volume":"343","author":"CA Diebolder","year":"2014","unstructured":"Diebolder, C. A. et al. Complement is activated by IgG hexamers assembled at the cell surface. Science 343, 1260\u20131263 (2014).","journal-title":"Science"},{"key":"766_CR72","doi-asserted-by":"publisher","first-page":"654652","DOI":"10.3389\/fimmu.2021.654652","volume":"12","author":"Y Ding","year":"2021","unstructured":"Ding, Y. et al. The spectrum of C4d deposition in renal biopsies of lupus nephritis patients. Front. Immunol. 12, 654652 (2021).","journal-title":"Front. Immunol."},{"key":"766_CR73","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1172\/JCI107562","volume":"53","author":"PJ Verroust","year":"1974","unstructured":"Verroust, P. J., Wilson, C. B., Cooper, N. R., Edgington, T. S. & Dixon, F. J. Glomerular complement components in human glomerulonephritis. J. Clin. Invest. 53, 77\u201384 (1974).","journal-title":"J. Clin. Invest."},{"key":"766_CR74","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/j.semnephrol.2013.08.004","volume":"33","author":"H Ma","year":"2013","unstructured":"Ma, H., Sandor, D. G. & Beck, L. H. Jr The role of complement in membranous nephropathy. Semin. Nephrol. 33, 531\u2013542 (2013).","journal-title":"Semin. Nephrol."},{"key":"766_CR75","doi-asserted-by":"publisher","first-page":"2519","DOI":"10.1172\/JCI85265","volume":"126","author":"NM Tomas","year":"2016","unstructured":"Tomas, N. M. et al. Autoantibodies against thrombospondin type 1 domain-containing 7A induce membranous nephropathy. J. Clin. Invest. 126, 2519\u20132532 (2016).","journal-title":"J. Clin. Invest."},{"key":"766_CR76","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.2215\/CJN.02170312","volume":"7","author":"C Murtas","year":"2012","unstructured":"Murtas, C. et al. Coexistence of different circulating anti-podocyte antibodies in membranous nephropathy. Clin. J. Am. Soc. Nephrol. 7, 1394\u20131400 (2012).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"766_CR77","first-page":"415","volume":"64","author":"JS van der Zee","year":"1986","unstructured":"van der Zee, J. S., van Swieten, P. & Aalberse, R. C. Inhibition of complement activation by IgG4 antibodies. Clin. Exp. Immunol. 64, 415\u2013422 (1986).","journal-title":"Clin. Exp. Immunol."},{"key":"766_CR78","first-page":"1391","volume":"26","author":"JF Val-Bernal","year":"2011","unstructured":"Val-Bernal, J. F., Garijo, M. F., Val, D., Rodrigo, E. & Arias, M. C4d immunohistochemical staining is a sensitive method to confirm immunoreactant deposition in formalin-fixed paraffin-embedded tissue in membranous glomerulonephritis. Histol. Histopathol. 26, 1391\u20131397 (2011).","journal-title":"Histol. Histopathol."},{"key":"766_CR79","doi-asserted-by":"publisher","unstructured":"Haddad, G. et al. Altered glycosylation of IgG4 promotes lectin complement pathway activation in anti-PLA2R1-associated membranous nephropathy. J. Clin. Invest. 131, https:\/\/doi.org\/10.1172\/JCI140453 (2021).","DOI":"10.1172\/JCI140453"},{"key":"766_CR80","doi-asserted-by":"publisher","first-page":"3539","DOI":"10.1681\/ASN.2015101155","volume":"27","author":"S Bally","year":"2016","unstructured":"Bally, S. et al. Phospholipase A2 receptor-related membranous nephropathy and mannan-binding lectin deficiency. J. Am. Soc. Nephrol. 27, 3539\u20133544 (2016).","journal-title":"J. Am. Soc. Nephrol."},{"key":"766_CR81","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1093\/ndt\/gfh008","volume":"19","author":"K Lhotta","year":"2004","unstructured":"Lhotta, K., Wurzner, R., Rumpelt, H. J., Eder, P. & Mayer, G. Membranous nephropathy in a patient with hereditary complete complement C4 deficiency. Nephrol. Dial. Transpl. 19, 990\u2013993 (2004).","journal-title":"Nephrol. Dial. Transpl."},{"key":"766_CR82","first-page":"185","volume":"135","author":"PJ Baker","year":"1989","unstructured":"Baker, P. J. et al. Depletion of C6 prevents development of proteinuria in experimental membranous nephropathy in rats. Am. J. Pathol. 135, 185\u2013194 (1989).","journal-title":"Am. J. Pathol."},{"key":"766_CR83","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1681\/ASN.2005010096","volume":"16","author":"PN Cunningham","year":"2005","unstructured":"Cunningham, P. N. & Quigg, R. J. Contrasting roles of complement activation and its regulation in membranous nephropathy. J. Am. Soc. Nephrol. 16, 1214\u20131222 (2005).","journal-title":"J. Am. Soc. Nephrol."},{"key":"766_CR84","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.1681\/ASN.2021101384","volume":"33","author":"S Gao","year":"2022","unstructured":"Gao, S., Cui, Z. & Zhao, M. H. Complement C3a and C3a receptor activation mediates podocyte injuries in the mechanism of primary membranous nephropathy. J. Am. Soc. Nephrol. 33, 1742\u20131756 (2022).","journal-title":"J. Am. Soc. Nephrol."},{"key":"766_CR85","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/S0065-2776(01)76021-X","volume":"76","author":"MC Pickering","year":"2000","unstructured":"Pickering, M. C., Botto, M., Taylor, P. R., Lachmann, P. J. & Walport, M. J. Systemic lupus erythematosus, complement deficiency, and apoptosis. Adv. Immunol. 76, 227\u2013324 (2000).","journal-title":"Adv. Immunol."},{"key":"766_CR86","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1084\/jem.192.3.359","volume":"192","author":"PR Taylor","year":"2000","unstructured":"Taylor, P. R. et al. A hierarchical role for classical pathway complement proteins in the clearance of apoptotic cells in vivo. J. Exp. Med. 192, 359\u2013366 (2000).","journal-title":"J. Exp. Med."},{"key":"766_CR87","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1177\/0961203310371154","volume":"19","author":"DJ Birmingham","year":"2010","unstructured":"Birmingham, D. J. et al. The complex nature of serum C3 and C4 as biomarkers of lupus renal flare. Lupus 19, 1272\u20131280 (2010).","journal-title":"Lupus"},{"key":"766_CR88","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1002\/art.40747","volume":"71","author":"AHJ Kim","year":"2019","unstructured":"Kim, A. H. J. et al. Association of blood concentrations of complement split product iC3b and serum C3 with systemic lupus erythematosus disease activity. Arthritis Rheumatol. 71, 420\u2013430 (2019).","journal-title":"Arthritis Rheumatol."},{"key":"766_CR89","doi-asserted-by":"publisher","first-page":"582737","DOI":"10.3389\/fimmu.2020.582737","volume":"11","author":"M Martin","year":"2020","unstructured":"Martin, M. et al. Plasma C4d correlates with C4d deposition in kidneys and with treatment response in lupus nephritis patients. Front. Immunol. 11, 582737 (2020).","journal-title":"Front. Immunol."},{"key":"766_CR90","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1093\/ajcp\/83.4.415","volume":"83","author":"JC Jennette","year":"1985","unstructured":"Jennette, J. C. & Hipp, C. G. Immunohistopathologic evaluation of C1q in 800 renal biopsy specimens. Am. J. Clin. Pathol. 83, 415\u2013420 (1985).","journal-title":"Am. J. Clin. Pathol."},{"key":"766_CR91","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/s10875-015-0137-5","volume":"35","author":"AJ Turley","year":"2015","unstructured":"Turley, A. J. et al. Spectrum and management of complement immunodeficiencies (excluding hereditary angioedema) across Europe. J. Clin. Immunol. 35, 199\u2013205 (2015).","journal-title":"J. Clin. Immunol."},{"key":"766_CR92","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1111\/j.1523-1755.2004.00371.x","volume":"65","author":"MK Elliott","year":"2004","unstructured":"Elliott, M. K. et al. Effects of complement factor D deficiency on the renal disease of MRL\/lpr mice. Kidney Int. 65, 129\u2013138 (2004).","journal-title":"Kidney Int."},{"key":"766_CR93","doi-asserted-by":"publisher","first-page":"786","DOI":"10.4049\/jimmunol.164.2.786","volume":"164","author":"H Watanabe","year":"2000","unstructured":"Watanabe, H. et al. Modulation of renal disease in MRL\/lpr mice genetically deficient in the alternative complement pathway factor B. J. Immunol. 164, 786\u2013794 (2000).","journal-title":"J. Immunol."},{"key":"766_CR94","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1056\/NEJMoa0910500","volume":"363","author":"V Pedchenko","year":"2010","unstructured":"Pedchenko, V. et al. Molecular architecture of the Goodpasture autoantigen in anti-GBM nephritis. N. Engl. J. Med. 363, 343\u2013354 (2010).","journal-title":"N. Engl. J. Med."},{"key":"766_CR95","first-page":"341","volume":"69","author":"C Bowman","year":"1987","unstructured":"Bowman, C., Ambrus, K. & Lockwood, C. M. Restriction of human IgG subclass expression in the population of auto-antibodies to glomerular basement membrane. Clin. Exp. Immunol. 69, 341\u2013349 (1987).","journal-title":"Clin. Exp. Immunol."},{"key":"766_CR96","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0091250","volume":"9","author":"R Ma","year":"2014","unstructured":"Ma, R. et al. The alternative pathway of complement activation may be involved in the renal damage of human anti-glomerular basement membrane disease. PLoS One 9, e91250 (2014).","journal-title":"PLoS One"},{"key":"766_CR97","doi-asserted-by":"publisher","first-page":"4553","DOI":"10.4049\/jimmunol.160.9.4553","volume":"160","author":"RJ Quigg","year":"1998","unstructured":"Quigg, R. J. et al. Blockade of antibody-induced glomerulonephritis with Crry-Ig, a soluble murine complement inhibitor. J. Immunol. 160, 4553\u20134560 (1998).","journal-title":"J. Immunol."},{"key":"766_CR98","doi-asserted-by":"publisher","first-page":"63","DOI":"10.2215\/CJN.04290417","volume":"13","author":"EE van Daalen","year":"2018","unstructured":"van Daalen, E. E. et al. Predicting outcome in patients with anti-GBM glomerulonephritis. Clin. J. Am. Soc. Nephrol. 13, 63\u201372 (2018).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"766_CR99","doi-asserted-by":"publisher","first-page":"2713","DOI":"10.1016\/j.ekir.2021.07.001","volume":"6","author":"P Nithagon","year":"2021","unstructured":"Nithagon, P. et al. Eculizumab and complement activation in anti-glomerular basement membrane disease. Kidney Int. Rep. 6, 2713\u20132717 (2021).","journal-title":"Kidney Int. Rep."},{"key":"766_CR100","first-page":"676","volume":"18","author":"M Haas","year":"2005","unstructured":"Haas, M. Histology and immunohistology of IgA nephropathy. J. Nephrol. 18, 676\u2013680 (2005).","journal-title":"J. Nephrol."},{"key":"766_CR101","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0040495","volume":"7","author":"SJ Kim","year":"2012","unstructured":"Kim, S. J. et al. Decreased circulating C3 levels and mesangial C3 deposition predict renal outcome in patients with IgA nephropathy. PLoS One 7, e40495 (2012).","journal-title":"PLoS One"},{"key":"766_CR102","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1002\/eji.1830170304","volume":"17","author":"PS Hiemstra","year":"1987","unstructured":"Hiemstra, P. S., Gorter, A., Stuurman, M. E., Van Es, L. A. & Daha, M. R. Activation of the alternative pathway of complement by human serum IgA. Eur. J. Immunol. 17, 321\u2013326 (1987).","journal-title":"Eur. J. Immunol."},{"key":"766_CR103","first-page":"629","volume":"118","author":"H Suzuki","year":"2008","unstructured":"Suzuki, H. et al. IgA1-secreting cell lines from patients with IgA nephropathy produce aberrantly glycosylated IgA1. J. Clin. Invest. 118, 629\u2013639 (2008).","journal-title":"J. Clin. Invest."},{"key":"766_CR104","first-page":"1668","volume":"119","author":"H Suzuki","year":"2009","unstructured":"Suzuki, H. et al. Aberrantly glycosylated IgA1 in IgA nephropathy patients is recognized by IgG antibodies with restricted heterogeneity. J. Clin. Invest. 119, 1668\u20131677 (2009).","journal-title":"J. Clin. Invest."},{"key":"766_CR105","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1681\/ASN.2018111156","volume":"30","author":"DV Rizk","year":"2019","unstructured":"Rizk, D. V. et al. Glomerular immunodeposits of patients with IgA nephropathy are enriched for IgG autoantibodies specific for galactose-deficient IgA1. J. Am. Soc. Nephrol. 30, 2017\u20132026 (2019).","journal-title":"J. Am. Soc. Nephrol."},{"key":"766_CR106","doi-asserted-by":"publisher","first-page":"897","DOI":"10.2215\/CJN.09710913","volume":"9","author":"M Espinosa","year":"2014","unstructured":"Espinosa, M. et al. Association of C4d deposition with clinical outcomes in IgA nephropathy. Clin. J. Am. Soc. Nephrol. 9, 897\u2013904 (2014).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"766_CR107","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-84715-7","volume":"11","author":"L Tan","year":"2021","unstructured":"Tan, L. et al. A multicenter, prospective, observational study to determine association of mesangial C1q deposition with renal outcomes in IgA nephropathy. Sci. Rep. 11, 5467 (2021).","journal-title":"Sci. Rep."},{"key":"766_CR108","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1016\/j.xkme.2021.06.009","volume":"3","author":"Y Jiang","year":"2021","unstructured":"Jiang, Y. et al. Glomerular C4d deposition and kidney disease progression in IgA nephropathy: a systematic review and meta-analysis. Kidney Med. 3, 1014\u20131021 (2021).","journal-title":"Kidney Med."},{"key":"766_CR109","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s12882-021-02237-w","volume":"22","author":"L Wu","year":"2021","unstructured":"Wu, L. et al. Immunofluorescence deposits in the mesangial area and glomerular capillary loops did not affect the prognosis of immunoglobulin a nephropathy except C1q:a single-center retrospective study. BMC Nephrol. 22, 43 (2021).","journal-title":"BMC Nephrol."},{"key":"766_CR110","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1136\/bmj.3.5875.326","volume":"3","author":"DJ Evans","year":"1973","unstructured":"Evans, D. J. et al. Glomerular deposition of properdin in Henoch-Schonlein syndrome and idiopathic focal nephritis. Br. Med. J. 3, 326\u2013328 (1973).","journal-title":"Br. Med. J."},{"key":"766_CR111","doi-asserted-by":"publisher","first-page":"638309","DOI":"10.3389\/fimmu.2021.638309","volume":"12","author":"YL Chiu","year":"2021","unstructured":"Chiu, Y. L. et al. Alternative complement pathway is activated and associated with galactose-deficient IgA1 antibody in IgA nephropathy patients. Front. Immunol. 12, 638309 (2021).","journal-title":"Front. Immunol."},{"key":"766_CR112","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0060352","volume":"8","author":"LV Holmes","year":"2013","unstructured":"Holmes, L. V. et al. Determining the population frequency of the CFHR3\/CFHR1 deletion at 1q32. PLoS One 8, e60352 (2013).","journal-title":"PLoS One"},{"key":"766_CR113","doi-asserted-by":"publisher","first-page":"3187","DOI":"10.1681\/ASN.2015111210","volume":"27","author":"J Xie","year":"2016","unstructured":"Xie, J. et al. Fine mapping implicates a deletion of CFHR1 and CFHR3 in protection from IgA nephropathy in Han Chinese. J. Am. Soc. Nephrol. 27, 3187\u20133194 (2016).","journal-title":"J. Am. Soc. Nephrol."},{"key":"766_CR114","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1038\/ng.3118","volume":"46","author":"K Kiryluk","year":"2014","unstructured":"Kiryluk, K. et al. Discovery of new risk loci for IgA nephropathy implicates genes involved in immunity against intestinal pathogens. Nat. Genet. 46, 1187\u20131196 (2014).","journal-title":"Nat. Genet."},{"key":"766_CR115","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1053\/ajkd.2002.29873","volume":"39","author":"B Murphy","year":"2002","unstructured":"Murphy, B., Georgiou, T., Machet, D., Hill, P. & McRae, J. Factor H-related protein-5: a novel component of human glomerular immune deposits. Am. J. Kidney Dis. 39, 24\u201327 (2002).","journal-title":"Am. J. Kidney Dis."},{"key":"766_CR116","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1016\/j.ekir.2017.11.015","volume":"3","author":"NR Medjeral-Thomas","year":"2018","unstructured":"Medjeral-Thomas, N. R. et al. Progressive IgA nephropathy is associated with low circulating mannan-binding lectin-associated serine protease-3 (MASP-3) and increased glomerular factor H-related protein-5 (FHR5) deposition. Kidney Int. Rep. 3, 426\u2013438 (2018).","journal-title":"Kidney Int. Rep."},{"key":"766_CR117","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1016\/j.kint.2017.03.041","volume":"92","author":"A Tortajada","year":"2017","unstructured":"Tortajada, A. et al. Elevated factor H-related protein 1 and factor H pathogenic variants decrease complement regulation in IgA nephropathy. Kidney Int. 92, 953\u2013963 (2017).","journal-title":"Kidney Int."},{"key":"766_CR118","doi-asserted-by":"publisher","first-page":"2894","DOI":"10.1681\/ASN.2015010012","volume":"27","author":"YL Zhai","year":"2016","unstructured":"Zhai, Y. L. et al. Rare variants in the complement factor H-related protein 5 gene contribute to genetic susceptibility to IgA nephropathy. J. Am. Soc. Nephrol. 27, 2894\u20132905 (2016).","journal-title":"J. Am. Soc. Nephrol."},{"key":"766_CR119","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1053\/ajkd.1998.v32.pm9669443","volume":"32","author":"AA Harris","year":"1998","unstructured":"Harris, A. A., Falk, R. J. & Jennette, J. C. Crescentic glomerulonephritis with a paucity of glomerular immunoglobulin localization. Am. J. Kidney Dis. 32, 179\u2013184 (1998).","journal-title":"Am. J. Kidney Dis."},{"key":"766_CR120","doi-asserted-by":"publisher","first-page":"52","DOI":"10.2353\/ajpath.2007.060573","volume":"170","author":"H Xiao","year":"2007","unstructured":"Xiao, H., Schreiber, A., Heeringa, P., Falk, R. J. & Jennette, J. C. Alternative complement pathway in the pathogenesis of disease mediated by anti-neutrophil cytoplasmic autoantibodies. Am. J. Pathol. 170, 52\u201364 (2007).","journal-title":"Am. J. Pathol."},{"key":"766_CR121","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1681\/ASN.2013020143","volume":"25","author":"H Xiao","year":"2014","unstructured":"Xiao, H. et al. C5a receptor (CD88) blockade protects against MPO-ANCA GN. J. Am. Soc. Nephrol. 25, 225\u2013231 (2014).","journal-title":"J. Am. Soc. Nephrol."},{"key":"766_CR122","doi-asserted-by":"publisher","first-page":"2145","DOI":"10.1111\/j.1523-1755.2004.00632.x","volume":"65","author":"M Haas","year":"2004","unstructured":"Haas, M. & Eustace, J. A. Immune complex deposits in ANCA-associated crescentic glomerulonephritis: a study of 126 cases. Kidney Int. 65, 2145\u20132152 (2004).","journal-title":"Kidney Int."},{"key":"766_CR123","doi-asserted-by":"publisher","first-page":"R140","DOI":"10.1186\/ar3873","volume":"14","author":"J Yuan","year":"2012","unstructured":"Yuan, J. et al. C5a and its receptors in human anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis. Arthritis Res. Ther. 14, R140 (2012).","journal-title":"Arthritis Res. Ther."},{"key":"766_CR124","doi-asserted-by":"publisher","first-page":"1884","DOI":"10.2215\/CJN.02790313","volume":"8","author":"SJ Gou","year":"2013","unstructured":"Gou, S. J., Yuan, J., Wang, C., Zhao, M. H. & Chen, M. Alternative complement pathway activation products in urine and kidneys of patients with ANCA-associated GN. Clin. J. Am. Soc. Nephrol. 8, 1884\u20131891 (2013).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"766_CR125","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1038\/ki.2012.313","volume":"83","author":"SJ Gou","year":"2013","unstructured":"Gou, S. J., Yuan, J., Chen, M., Yu, F. & Zhao, M. H. Circulating complement activation in patients with anti-neutrophil cytoplasmic antibody-associated vasculitis. Kidney Int. 83, 129\u2013137 (2013).","journal-title":"Kidney Int."},{"key":"766_CR126","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1056\/NEJMoa2023386","volume":"384","author":"DRW Jayne","year":"2021","unstructured":"Jayne, D. R. W., Merkel, P. A., Schall, T. J., Bekker, P. & Group, A. S. Avacopan for the treatment of ANCA-associated vasculitis. N. Engl. J. Med. 384, 599\u2013609 (2021).","journal-title":"N. Engl. J. Med."},{"key":"766_CR127","doi-asserted-by":"publisher","first-page":"2756","DOI":"10.1681\/ASN.2016111179","volume":"28","author":"DRW Jayne","year":"2017","unstructured":"Jayne, D. R. W. et al. Randomized trial of C5a receptor inhibitor avacopan in ANCA-associated vasculitis. J. Am. Soc. Nephrol. 28, 2756\u20132767 (2017).","journal-title":"J. Am. Soc. Nephrol."},{"key":"766_CR128","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1056\/NEJMoa0909905","volume":"363","author":"JH Stone","year":"2010","unstructured":"Stone, J. H. et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N. Engl. J. Med. 363, 221\u2013232 (2010).","journal-title":"N. Engl. J. Med."},{"key":"766_CR129","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1056\/NEJMoa0909169","volume":"363","author":"RB Jones","year":"2010","unstructured":"Jones, R. B. et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N. Engl. J. Med. 363, 211\u2013220 (2010).","journal-title":"N. Engl. J. Med."},{"key":"766_CR130","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1111\/jdi.13739","volume":"13","author":"Y Jiao","year":"2022","unstructured":"Jiao, Y. et al. Activation of complement C1q and C3 in glomeruli might accelerate the progression of diabetic nephropathy: evidence from transcriptomic data and renal histopathology. J. Diabetes Investig. 13, 839\u2013849 (2022).","journal-title":"J. Diabetes Investig."},{"key":"766_CR131","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.3389\/fimmu.2020.02073","volume":"11","author":"S Duan","year":"2020","unstructured":"Duan, S. et al. Association of glomerular complement C4c deposition with the progression of diabetic kidney disease in patients with type 2 diabetes. Front. Immunol. 11, 2073 (2020).","journal-title":"Front. Immunol."},{"key":"766_CR132","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1002\/dmrr.1079","volume":"26","author":"J Fortpied","year":"2010","unstructured":"Fortpied, J., Vertommen, D. & Van Schaftingen, E. Binding of mannose-binding lectin to fructosamines: a potential link between hyperglycaemia and complement activation in diabetes. Diabetes Metab. Res. Rev. 26, 254\u2013260 (2010).","journal-title":"Diabetes Metab. Res. Rev."},{"key":"766_CR133","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1007\/s00125-007-0686-0","volume":"50","author":"J Ostergaard","year":"2007","unstructured":"Ostergaard, J. et al. Mannose-binding lectin deficiency attenuates renal changes in a streptozotocin-induced model of type 1 diabetes in mice. Diabetologia 50, 1541\u20131549 (2007).","journal-title":"Diabetologia"},{"key":"766_CR134","doi-asserted-by":"publisher","first-page":"678381","DOI":"10.1155\/2012\/678381","volume":"2012","author":"JA Ostergaard","year":"2012","unstructured":"Ostergaard, J. A. et al. Mannan-binding lectin in diabetic kidney disease: the impact of mouse genetics in a type 1 diabetes model. Exp. Diabetes Res. 2012, 678381 (2012).","journal-title":"Exp. Diabetes Res."},{"key":"766_CR135","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1111\/sji.12027","volume":"77","author":"JA Ostergaard","year":"2013","unstructured":"Ostergaard, J. A. et al. Diabetes-induced changes in mannan-binding lectin levels and complement activation in a mouse model of type 1 diabetes. Scand. J. Immunol. 77, 187\u2013194 (2013).","journal-title":"Scand. J. Immunol."},{"key":"766_CR136","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1007\/s00125-004-1594-1","volume":"48","author":"M Saraheimo","year":"2005","unstructured":"Saraheimo, M. et al. Increased levels of mannan-binding lectin in type 1 diabetic patients with incipient and overt nephropathy. Diabetologia 48, 198\u2013202 (2005).","journal-title":"Diabetologia"},{"key":"766_CR137","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1007\/s00125-010-1742-8","volume":"53","author":"TK Hansen","year":"2010","unstructured":"Hansen, T. K. et al. Association between mannose-binding lectin, high-sensitivity C-reactive protein and the progression of diabetic nephropathy in type 1 diabetes. Diabetologia 53, 1517\u20131524 (2010).","journal-title":"Diabetologia"},{"key":"766_CR138","doi-asserted-by":"publisher","DOI":"10.1186\/s12014-019-9253-1","volume":"16","author":"H Lu","year":"2019","unstructured":"Lu, H., Deng, S., Zheng, M. & Hu, K. iTRAQ plasma proteomics analysis for candidate biomarkers of type 2 incipient diabetic nephropathy. Clin. Proteom. 16, 33 (2019).","journal-title":"Clin. Proteom."},{"key":"766_CR139","doi-asserted-by":"publisher","first-page":"2653","DOI":"10.2337\/diabetes.53.10.2653","volume":"53","author":"X Qin","year":"2004","unstructured":"Qin, X. et al. Glycation inactivation of the complement regulatory protein CD59: a possible role in the pathogenesis of the vascular complications of human diabetes. Diabetes 53, 2653\u20132661 (2004).","journal-title":"Diabetes"},{"key":"766_CR140","doi-asserted-by":"publisher","first-page":"5450","DOI":"10.1073\/pnas.97.10.5450","volume":"97","author":"J Acosta","year":"2000","unstructured":"Acosta, J. et al. Molecular basis for a link between complement and the vascular complications of diabetes. Proc. Natl Acad. Sci. USA 97, 5450\u20135455 (2000).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"766_CR141","doi-asserted-by":"publisher","first-page":"981","DOI":"10.2337\/dc16-2598","volume":"40","author":"P Ghosh","year":"2017","unstructured":"Ghosh, P. et al. Plasma glycated CD59, a novel biomarker for detection of pregnancy-induced glucose intolerance. Diabetes Care 40, 981\u2013984 (2017).","journal-title":"Diabetes Care"},{"key":"766_CR142","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20191699","author":"A Angeletti","year":"2020","unstructured":"Angeletti, A. et al. Loss of decay-accelerating factor triggers podocyte injury and glomerulosclerosis. J. Exp. Med. https:\/\/doi.org\/10.1084\/jem.20191699 (2020).","journal-title":"J. Exp. Med."},{"key":"766_CR143","doi-asserted-by":"publisher","first-page":"681","DOI":"10.3389\/fgene.2019.00681","volume":"10","author":"E Valoti","year":"2019","unstructured":"Valoti, E. et al. Impact of a complement factor H gene variant on renal dysfunction, cardiovascular events, and response to ACE inhibitor therapy in type 2 diabetes. Front. Genet. 10, 681 (2019).","journal-title":"Front. Genet."},{"key":"766_CR144","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1038\/s41572-020-0196-7","volume":"6","author":"JB Kopp","year":"2020","unstructured":"Kopp, J. B. et al. Podocytopathies. Nat. Rev. Dis. Prim. 6, 68 (2020).","journal-title":"Nat. Rev. Dis. Prim."},{"key":"766_CR145","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.2215\/CJN.01190216","volume":"11","author":"YM Zhang","year":"2016","unstructured":"Zhang, Y. M. et al. Clinical significance of IgM and C3 glomerular deposition in primary focal segmental glomerulosclerosis. Clin. J. Am. Soc. Nephrol. 11, 1582\u20131589 (2016).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"766_CR146","doi-asserted-by":"publisher","first-page":"F505","DOI":"10.1152\/ajprenal.00041.2021","volume":"321","author":"H Trachtman","year":"2021","unstructured":"Trachtman, H. et al. Natural antibody and complement activation characterize patients with idiopathic nephrotic syndrome. Am. J. Physiol. Renal Physiol. 321, F505\u2013F516 (2021).","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"766_CR147","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1681\/ASN.2012020187","volume":"24","author":"D Strassheim","year":"2013","unstructured":"Strassheim, D. et al. IgM contributes to glomerular injury in FSGS. J. Am. Soc. Nephrol. 24, 393\u2013406 (2013).","journal-title":"J. Am. Soc. Nephrol."},{"key":"766_CR148","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1016\/j.kint.2019.04.028","volume":"96","author":"NA van de Lest","year":"2019","unstructured":"van de Lest, N. A. et al. Glomerular C4d deposition can precede the development of focal segmental glomerulosclerosis. Kidney Int. 96, 738\u2013749 (2019).","journal-title":"Kidney Int."},{"key":"766_CR149","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0136558","volume":"10","author":"JM Thurman","year":"2015","unstructured":"Thurman, J. M. et al. Complement activation in patients with focal segmental glomerulosclerosis. PLoS One 10, e0136558 (2015).","journal-title":"PLoS One"},{"key":"766_CR150","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0234934","volume":"15","author":"J Huang","year":"2020","unstructured":"Huang, J. et al. Complement activation profile of patients with primary focal segmental glomerulosclerosis. PLoS One 15, e0234934 (2020).","journal-title":"PLoS One"},{"key":"766_CR151","doi-asserted-by":"publisher","first-page":"F555","DOI":"10.1152\/ajprenal.00403.2006","volume":"293","author":"AM Lenderink","year":"2007","unstructured":"Lenderink, A. M. et al. The alternative pathway of complement is activated in the glomeruli and tubulointerstitium of mice with adriamycin nephropathy. Am. J. Physiol. Renal Physiol. 293, F555\u2013F564 (2007).","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"766_CR152","doi-asserted-by":"publisher","first-page":"4094","DOI":"10.4049\/jimmunol.177.6.4094","volume":"177","author":"D Turnberg","year":"2006","unstructured":"Turnberg, D. et al. Complement activation contributes to both glomerular and tubulointerstitial damage in adriamycin nephropathy in mice. J. Immunol. 177, 4094\u20134102 (2006).","journal-title":"J. Immunol."},{"key":"766_CR153","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.2215\/CJN.00830208","volume":"3","author":"S Hisano","year":"2008","unstructured":"Hisano, S. et al. Clinicopathologic correlation and outcome of C1q nephropathy. Clin. J. Am. Soc. Nephrol. 3, 1637\u20131643 (2008).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"766_CR154","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.1681\/ASN.2007080929","volume":"19","author":"A Vizjak","year":"2008","unstructured":"Vizjak, A. et al. Pathology, clinical presentations, and outcomes of C1q nephropathy. J. Am. Soc. Nephrol. 19, 2237\u20132244 (2008).","journal-title":"J. Am. Soc. Nephrol."},{"key":"766_CR155","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1007\/s00467-013-2692-4","volume":"29","author":"VN Gunasekara","year":"2014","unstructured":"Gunasekara, V. N., Sebire, N. J. & Tullus, K. C1q nephropathy in children: clinical characteristics and outcome. Pediatr. Nephrol. 29, 407\u2013413 (2014).","journal-title":"Pediatr. Nephrol."},{"key":"766_CR156","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.4049\/jimmunol.170.3.1517","volume":"170","author":"JM Thurman","year":"2003","unstructured":"Thurman, J. M., Ljubanovic, D., Edelstein, C. L., Gilkeson, G. S. & Holers, V. M. Lack of a functional alternative complement pathway ameliorates ischemic acute renal failure in mice. J. Immunol. 170, 1517\u20131523 (2003).","journal-title":"J. Immunol."},{"key":"766_CR157","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1172\/JCI24521","volume":"116","author":"JM Thurman","year":"2006","unstructured":"Thurman, J. M. et al. Altered renal tubular expression of the complement inhibitor Crry permits complement activation after ischemia\/reperfusion. J. Clin. Invest. 116, 357\u2013368 (2006).","journal-title":"J. Clin. Invest."},{"key":"766_CR158","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.1172\/JCI83000","volume":"126","author":"CA Farrar","year":"2016","unstructured":"Farrar, C. A. et al. Collectin-11 detects stress-induced L-fucose pattern to trigger renal epithelial injury. J. Clin. Invest. 126, 1911\u20131925 (2016).","journal-title":"J. Clin. Invest."},{"key":"766_CR159","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/j.kint.2020.09.033","volume":"99","author":"I Boudhabhay","year":"2021","unstructured":"Boudhabhay, I. et al. Complement activation is a crucial driver of acute kidney injury in rhabdomyolysis. Kidney Int. 99, 581\u2013597 (2021).","journal-title":"Kidney Int."},{"key":"766_CR160","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/s12882-018-0902-9","volume":"19","author":"ML Merchant","year":"2018","unstructured":"Merchant, M. L., Brier, M. E., Slaughter, M. S., Klein, J. B. & McLeish, K. R. Biomarker enhanced risk prediction for development of AKI after cardiac surgery. BMC Nephrol. 19, 102 (2018).","journal-title":"BMC Nephrol."},{"key":"766_CR161","doi-asserted-by":"publisher","first-page":"F650","DOI":"10.1152\/ajprenal.00130.2019","volume":"317","author":"J Laskowski","year":"2019","unstructured":"Laskowski, J., Philbrook, H. T., Parikh, C. R. & Thurman, J. M. Urine complement activation fragments are increased in patients with kidney injury after cardiac surgery. Am. J. Physiol. Renal Physiol. 317, F650\u2013F657 (2019).","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"766_CR162","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1038\/sj.ki.5002627","volume":"73","author":"M Mrug","year":"2008","unstructured":"Mrug, M. et al. Overexpression of innate immune response genes in a model of recessive polycystic kidney disease. Kidney Int. 73, 63\u201376 (2008).","journal-title":"Kidney Int."},{"key":"766_CR163","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1681\/ASN.2011050442","volume":"23","author":"J Zhou","year":"2012","unstructured":"Zhou, J. et al. Kidney injury accelerates cystogenesis via pathways modulated by heme oxygenase and complement. J. Am. Soc. Nephrol. 23, 1161\u20131171 (2012).","journal-title":"J. Am. Soc. Nephrol."},{"key":"766_CR164","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1111\/joim.12307","volume":"276","author":"M Mrug","year":"2014","unstructured":"Mrug, M. et al. Complement C3 activation in cyst fluid and urine from autosomal dominant polycystic kidney disease patients. J. Intern. Med. 276, 539\u2013540 (2014).","journal-title":"J. Intern. Med."},{"key":"766_CR165","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/ki.1994.247","volume":"46","author":"S Ichida","year":"1994","unstructured":"Ichida, S., Yuzawa, Y., Okada, H., Yoshioka, K. & Matsuo, S. Localization of the complement regulatory proteins in the normal human kidney. Kidney Int. 46, 89\u201396 (1994).","journal-title":"Kidney Int."},{"key":"766_CR166","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1038\/ki.1989.167","volume":"36","author":"FG Cosio","year":"1989","unstructured":"Cosio, F. G., Sedmak, D. D., Mahan, J. D. & Nahman, N. S. Jr. Localization of decay accelerating factor in normal and diseased kidneys. Kidney Int. 36, 100\u2013107 (1989).","journal-title":"Kidney Int."},{"key":"766_CR167","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1111\/j.1365-2249.1993.tb05998.x","volume":"94","author":"M Endoh","year":"1993","unstructured":"Endoh, M. et al. Immunohistochemical demonstration of membrane cofactor protein (MCP) of complement in normal and diseased kidney tissues. Clin. Exp. Immunol. 94, 182\u2013188 (1993).","journal-title":"Clin. Exp. Immunol."},{"key":"766_CR168","doi-asserted-by":"publisher","first-page":"877","DOI":"10.4049\/jimmunol.133.2.877","volume":"133","author":"PJ Baker","year":"1984","unstructured":"Baker, P. J., Adler, S., Yang, Y. & Couser, W. G. Complement activation by heat-killed human kidney cells: formation, activity, and stabilization of cell-bound C3 convertases. J. Immunol. 133, 877\u2013881 (1984).","journal-title":"J. Immunol."},{"key":"766_CR169","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1681\/ASN.V10169","volume":"10","author":"S Tang","year":"1999","unstructured":"Tang, S., Sheerin, N. S., Zhou, W., Brown, Z. & Sacks, S. H. Apical proteins stimulate complement synthesis by cultured human proximal tubular epithelial cells. J. Am. Soc. Nephrol. 10, 69\u201376 (1999).","journal-title":"J. Am. Soc. Nephrol."},{"key":"766_CR170","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1096\/fj.05-4747com","volume":"20","author":"CA Farrar","year":"2006","unstructured":"Farrar, C. A., Zhou, W., Lin, T. & Sacks, S. H. Local extravascular pool of C3 is a determinant of postischemic acute renal failure. FASEB J. 20, 217\u2013226 (2006).","journal-title":"FASEB J."},{"key":"766_CR171","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1056\/NEJMoa2027760","volume":"384","author":"A Roth","year":"2021","unstructured":"Roth, A. et al. Sutimlimab in cold agglutinin disease. N. Engl. J. Med. 384, 1323\u20131334 (2021).","journal-title":"N. Engl. J. Med."},{"key":"766_CR172","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1056\/NEJMoa2029073","volume":"384","author":"P Hillmen","year":"2021","unstructured":"Hillmen, P. et al. Pegcetacoplan versus eculizumab in paroxysmal nocturnal hemoglobinuria. N. Engl. J. Med. 384, 1028\u20131037 (2021).","journal-title":"N. Engl. J. Med."},{"key":"766_CR173","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/s00281-017-0655-8","volume":"40","author":"CL Harris","year":"2018","unstructured":"Harris, C. L. Expanding horizons in complement drug discovery: challenges and emerging strategies. Semin. Immunopathol. 40, 125\u2013140 (2018).","journal-title":"Semin. Immunopathol."},{"key":"766_CR174","doi-asserted-by":"publisher","first-page":"5525","DOI":"10.4049\/jimmunol.1501686","volume":"195","author":"E Stites","year":"2015","unstructured":"Stites, E., Le Quintrec, M. & Thurman, J. M. The complement system and antibody-mediated transplant rejection. J. Immunol. 195, 5525\u20135531 (2015).","journal-title":"J. Immunol."},{"key":"766_CR175","doi-asserted-by":"publisher","first-page":"2447","DOI":"10.1200\/JCO.21.02389","volume":"40","author":"SK Khaled","year":"2022","unstructured":"Khaled, S. K. et al. Narsoplimab, a Mannan-binding lectin-associated serine protease-2 inhibitor, for the treatment of adult hematopoietic stem-cell transplantation-associated thrombotic microangiopathy. J. Clin. Oncol. 40, 2447\u20132457 (2022).","journal-title":"J. Clin. Oncol."},{"key":"766_CR176","doi-asserted-by":"publisher","first-page":"2150","DOI":"10.1016\/j.ekir.2022.07.004","volume":"7","author":"AS Bomback","year":"2022","unstructured":"Bomback, A. S. et al. Alternative complement pathway inhibition with iptacopan for the treatment of C3 glomerulopathy-study design of the APPEAR-C3G trial. Kidney Int. Rep. 7, 2150\u20132159 (2022).","journal-title":"Kidney Int. Rep."},{"key":"766_CR177","doi-asserted-by":"publisher","DOI":"10.1172\/JCI152973","author":"H Hasturk","year":"2021","unstructured":"Hasturk, H. et al. Phase IIa clinical trial of complement C3 inhibitor AMY-101 in adults with periodontal inflammation. J. Clin. Invest. https:\/\/doi.org\/10.1172\/JCI152973 (2021).","journal-title":"J. Clin. Invest."},{"key":"766_CR178","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1186\/s12882-018-1160-6","volume":"19","author":"C Li","year":"2018","unstructured":"Li, C., Li, H., Wen, Y. B., Li, X. M. & Li, X. W. Analysis of predictive factors for immunosuppressive response in anti-phospholipase A2 receptor antibody positive membranous nephropathy. BMC Nephrol. 19, 354 (2018).","journal-title":"BMC Nephrol."},{"key":"766_CR179","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.2215\/CJN.10471013","volume":"9","author":"AP Bech","year":"2014","unstructured":"Bech, A. P., Hofstra, J. M., Brenchley, P. E. & Wetzels, J. F. Association of anti-PLA2R antibodies with outcomes after immunosuppressive therapy in idiopathic membranous nephropathy. Clin. J. Am. Soc. Nephrol. 9, 1386\u20131392 (2014).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"766_CR180","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1093\/rheumatology\/keu366","volume":"54","author":"J Robson","year":"2015","unstructured":"Robson, J. et al. Glucocorticoid treatment and damage in the anti-neutrophil cytoplasm antibody-associated vasculitides: long-term data from the European Vasculitis Study Group trials. Rheumatology 54, 471\u2013481 (2015).","journal-title":"Rheumatology"},{"key":"766_CR181","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1007\/s40674-017-0069-8","volume":"3","author":"G Stojan","year":"2017","unstructured":"Stojan, G. & Petri, M. The risk benefit ratio of glucocorticoids in SLE: have things changed over the past 40 years? Curr. Treatm. Opt. Rheumatol. 3, 164\u2013172 (2017).","journal-title":"Curr. Treatm. Opt. Rheumatol."},{"key":"766_CR182","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.131849","author":"M Morigi","year":"2020","unstructured":"Morigi, M. et al. C3a receptor blockade protects podocytes from injury in diabetic nephropathy. JCI Insight https:\/\/doi.org\/10.1172\/jci.insight.131849 (2020).","journal-title":"JCI Insight"},{"key":"766_CR183","doi-asserted-by":"publisher","first-page":"457","DOI":"10.4049\/jimmunol.141.2.457","volume":"141","author":"RH Carter","year":"1988","unstructured":"Carter, R. H., Spycher, M. O., Ng, Y. C., Hoffman, R. & Fearon, D. T. Synergistic interaction between complement receptor type 2 and membrane IgM on B lymphocytes. J. Immunol. 141, 457\u2013463 (1988).","journal-title":"J. Immunol."},{"key":"766_CR184","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1038\/ni.2499","volume":"14","author":"MG Strainic","year":"2013","unstructured":"Strainic, M. G., Shevach, E. M., An, F., Lin, F. & Medof, M. E. Absence of signaling into CD4+ cells via C3aR and C5aR enables autoinductive TGF-\u03b21 signaling and induction of Foxp3+ regulatory T cells. Nat. Immunol. 14, 162\u2013171 (2013).","journal-title":"Nat. Immunol."},{"key":"766_CR185","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1084\/jem.20041967","volume":"201","author":"PS Heeger","year":"2005","unstructured":"Heeger, P. S. et al. Decay-accelerating factor modulates induction of T cell immunity. J. Exp. Med. 201, 1523\u20131530 (2005).","journal-title":"J. Exp. Med."},{"key":"766_CR186","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1053\/j.ajkd.2021.07.025","volume":"79","author":"AS Bomback","year":"2022","unstructured":"Bomback, A. S. et al. Improving clinical trials for anticomplement therapies in complement-mediated glomerulopathies: report of a scientific workshop sponsored by the National Kidney Foundation. Am. J. Kidney Dis. 79, 570\u2013581 (2022).","journal-title":"Am. J. Kidney Dis."},{"key":"766_CR187","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1111\/j.1365-2796.1997.tb00018.x","volume":"242","author":"L Skattum","year":"1997","unstructured":"Skattum, L., Martensson, U. & Sjoholm, A. G. Hypocomplementaemia caused by C3 nephritic factors (C3 NeF): clinical findings and the coincidence of C3 NeF type II with anti-C1q autoantibodies. J. Intern. Med. 242, 455\u2013464 (1997).","journal-title":"J. Intern. Med."},{"key":"766_CR188","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1111\/imr.13156","volume":"313","author":"JM Thurman","year":"2023","unstructured":"Thurman, J. M. & Fremeaux-Bacchi, V. Alternative pathway diagnostics. Immunol. Rev. 313, 225\u2013238 (2023).","journal-title":"Immunol. Rev."},{"key":"766_CR189","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/BF00862594","volume":"2","author":"RJ Wyatt","year":"1988","unstructured":"Wyatt, R. J., Forristal, J., West, C. D., Sugimoto, S. & Curd, J. G. Complement profiles in acute post-streptococcal glomerulonephritis. Pediatr. Nephrol. 2, 219\u2013223 (1988).","journal-title":"Pediatr. Nephrol."},{"key":"766_CR190","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1038\/ki.1992.143","volume":"41","author":"PE Brenchley","year":"1992","unstructured":"Brenchley, P. E. et al. Urinary C3dg and C5b-9 indicate active immune disease in human membranous nephropathy. Kidney Int. 41, 933\u2013937 (1992).","journal-title":"Kidney Int."},{"key":"766_CR191","first-page":"397","volume":"8","author":"BM Coupes","year":"1993","unstructured":"Coupes, B. M., Kon, S. P., Brenchley, P. E., Short, C. D. & Mallick, N. P. The temporal relationship between urinary C5b-9 and C3dg and clinical parameters in human membranous nephropathy. Nephrol. Dial. Transplant. 8, 397\u2013401 (1993).","journal-title":"Nephrol. Dial. Transplant."},{"key":"766_CR192","doi-asserted-by":"publisher","first-page":"2438","DOI":"10.1182\/blood.2020009280","volume":"137","author":"F Fakhouri","year":"2021","unstructured":"Fakhouri, F. et al. Eculizumab discontinuation in children and adults with atypical hemolytic-uremic syndrome: a prospective multicenter study. Blood 137, 2438\u20132449 (2021).","journal-title":"Blood"},{"key":"766_CR193","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/0002-9343(78)90180-8","volume":"64","author":"GS Hill","year":"1978","unstructured":"Hill, G. S., Hinglais, N., Tron, F. & Bach, J. F. Systemic lupus erythematosus. Morphologic correlations with immunologic and clinical data at the time of biopsy. Am. J. Med. 64, 61\u201379 (1978).","journal-title":"Am. J. Med."},{"key":"766_CR194","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1016\/j.ekir.2019.07.015","volume":"4","author":"CB Drachenberg","year":"2019","unstructured":"Drachenberg, C. B. et al. Epidemiology and pathophysiology of glomerular C4d staining in native kidney biopsies. Kidney Int. Rep. 4, 1555\u20131567 (2019).","journal-title":"Kidney Int. Rep."},{"key":"766_CR195","doi-asserted-by":"publisher","first-page":"554","DOI":"10.2215\/CJN.04760512","volume":"8","author":"V Fremeaux-Bacchi","year":"2013","unstructured":"Fremeaux-Bacchi, V. et al. Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults. Clin. J. Am. Soc. Nephrol. 8, 554\u2013562 (2013).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"766_CR196","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1182\/blood-2005-10-007252","volume":"108","author":"J Caprioli","year":"2006","unstructured":"Caprioli, J. et al. Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome. Blood 108, 1267\u20131279 (2006).","journal-title":"Blood"},{"key":"766_CR197","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1111\/ajt.12077","volume":"13","author":"M Le Quintrec","year":"2013","unstructured":"Le Quintrec, M. et al. Complement genes strongly predict recurrence and graft outcome in adult renal transplant recipients with atypical hemolytic and uremic syndrome. Am. J. Transplant. 13, 663\u2013675 (2013).","journal-title":"Am. J. Transplant."},{"key":"766_CR198","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.4049\/jimmunol.1500793","volume":"196","author":"B Renner","year":"2016","unstructured":"Renner, B. et al. Annexin A2 enhances complement activation by inhibiting factor H. J. Immunol. 196, 1355\u20131365 (2016).","journal-title":"J. Immunol."},{"key":"766_CR199","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.2215\/CJN.02210310","volume":"5","author":"M Noris","year":"2010","unstructured":"Noris, M. et al. Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin. J. Am. Soc. Nephrol. 5, 1844\u20131859 (2010).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"766_CR200","doi-asserted-by":"publisher","first-page":"721","DOI":"10.3389\/fimmu.2018.00721","volume":"9","author":"E Karasu","year":"2018","unstructured":"Karasu, E., Eisenhardt, S. U., Harant, J. & Huber-Lang, M. Extracellular vesicles: packages sent with complement. Front. Immunol. 9, 721 (2018).","journal-title":"Front. Immunol."},{"key":"766_CR201","doi-asserted-by":"publisher","first-page":"58","DOI":"10.4103\/0971-4065.179369","volume":"27","author":"SK Sethi","year":"2017","unstructured":"Sethi, S. K. et al. Eculizumab for atypical hemolytic-uremic syndrome in India: first report from India and the challenges faced. Indian J. Nephrol. 27, 58\u201361 (2017).","journal-title":"Indian J. Nephrol."},{"key":"766_CR202","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/j.mayocpiqo.2022.03.005","volume":"6","author":"M Sridharan","year":"2022","unstructured":"Sridharan, M., Go, R. S. & Willrich, M. A. V. Clinical utility and potential cost savings of pharmacologic monitoring of eculizumab for complement-mediated thrombotic microangiopathy. Mayo Clin. Proc. Innov. Qual. Outcomes 6, 458\u2013464 (2022).","journal-title":"Mayo Clin. Proc. Innov. Qual. Outcomes"},{"key":"766_CR203","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/S0140-6736(17)30062-4","volume":"390","author":"F Fakhouri","year":"2017","unstructured":"Fakhouri, F., Zuber, J., Fremeaux-Bacchi, V. & Loirat, C. Haemolytic uraemic syndrome. Lancet 390, 681\u2013696 (2017).","journal-title":"Lancet"},{"key":"766_CR204","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1038\/s41581-018-0107-2","volume":"15","author":"RJH Smith","year":"2019","unstructured":"Smith, R. J. H. et al. C3 glomerulopathy \u2014 understanding a rare complement-driven renal disease. Nat. Rev. Nephrol. 15, 129\u2013143 (2019).","journal-title":"Nat. Rev. Nephrol."},{"key":"766_CR205","doi-asserted-by":"publisher","first-page":"295","DOI":"10.2147\/CLEP.S245642","volume":"12","author":"K Yan","year":"2020","unstructured":"Yan, K., Desai, K., Gullapalli, L., Druyts, E. & Balijepalli, C. Epidemiology of atypical hemolytic uremic syndrome: a systematic literature review. Clin. Epidemiol. 12, 295\u2013305 (2020).","journal-title":"Clin. Epidemiol."},{"key":"766_CR206","doi-asserted-by":"publisher","first-page":"2447","DOI":"10.1681\/ASN.2007030356","volume":"18","author":"RJ Smith","year":"2007","unstructured":"Smith, R. J. et al. New approaches to the treatment of dense deposit disease. J. Am. Soc. Nephrol. 18, 2447\u20132456 (2007).","journal-title":"J. Am. Soc. Nephrol."},{"key":"766_CR207","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1016\/j.semnephrol.2013.08.003","volume":"33","author":"D Kavanagh","year":"2013","unstructured":"Kavanagh, D., Goodship, T. H. & Richards, A. Atypical hemolytic uremic syndrome. Semin. Nephrol. 33, 508\u2013530 (2013).","journal-title":"Semin. Nephrol."},{"key":"766_CR208","doi-asserted-by":"publisher","first-page":"22","DOI":"10.2215\/CJN.03480708","volume":"4","author":"SH Nasr","year":"2009","unstructured":"Nasr, S. H. et al. Dense deposit disease: clinicopathologic study of 32 pediatric and adult patients. Clin. J. Am. Soc. Nephrol. 4, 22\u201332 (2009).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"766_CR209","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1053\/j.ajkd.2013.07.011","volume":"63","author":"F Fakhouri","year":"2014","unstructured":"Fakhouri, F. et al. Insights from the use in clinical practice of eculizumab in adult patients with atypical hemolytic uremic syndrome affecting the native kidneys: an analysis of 19 cases. Am. J. Kidney Dis. 63, 40\u201348 (2014).","journal-title":"Am. J. Kidney Dis."},{"key":"766_CR210","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1038\/nrneph.2010.155","volume":"7","author":"J Zuber","year":"2011","unstructured":"Zuber, J. et al. New insights into postrenal transplant hemolytic uremic syndrome. Nat. Rev. Nephrol. 7, 23\u201335 (2011).","journal-title":"Nat. Rev. Nephrol."},{"key":"766_CR211","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1097\/01.md.0000111061.69212.59","volume":"83","author":"A Misra","year":"2004","unstructured":"Misra, A., Peethambaram, A. & Garg, A. Clinical features and metabolic and autoimmune derangements in acquired partial lipodystrophy: report of 35 cases and review of the literature. Medicine 83, 18\u201334 (2004).","journal-title":"Medicine"},{"key":"766_CR212","doi-asserted-by":"publisher","DOI":"10.1097\/ICB.0000000000000164","author":"LA Dalvin","year":"2015","unstructured":"Dalvin, L. A., Fervenza, F. C., Sethi, S. & Pulido, J. S. Shedding light on Fundus Drusen Associated with Membranoproliferative Glomerulonephritis: breaking stereotypes of types I, II, and III. Retin. Cases Brief. Rep. https:\/\/doi.org\/10.1097\/ICB.0000000000000164 (2015).","journal-title":"Retin. Cases Brief. Rep."},{"key":"766_CR213","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1182\/blood-2014-02-558296","volume":"124","author":"M Noris","year":"2014","unstructured":"Noris, M. et al. Dynamics of complement activation in aHUS and how to monitor eculizumab therapy. Blood 124, 1715\u20131726 (2014).","journal-title":"Blood"},{"key":"766_CR214","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2022.05.027","author":"S Chauvet","year":"2022","unstructured":"Chauvet, S. et al. Results from a national-wide retrospective cohort measure the impact of C3 and soluble C5b-9 levels on kidney outcomes in C3 glomerulopathy. Kidney Int. https:\/\/doi.org\/10.1016\/j.kint.2022.05.027 (2022).","journal-title":"Kidney Int."},{"key":"766_CR215","doi-asserted-by":"publisher","first-page":"607211","DOI":"10.3389\/fimmu.2020.607211","volume":"11","author":"Y Zhang","year":"2020","unstructured":"Zhang, Y. et al. Factor H autoantibodies and complement-mediated diseases. Front. Immunol. 11, 607211 (2020).","journal-title":"Front. Immunol."},{"key":"766_CR216","doi-asserted-by":"publisher","first-page":"886","DOI":"10.3389\/fimmu.2019.00886","volume":"10","author":"F Corvillo","year":"2019","unstructured":"Corvillo, F. et al. Nephritic factors: an overview of classification, diagnostic tools and clinical associations. Front. Immunol. 10, 886 (2019).","journal-title":"Front. Immunol."},{"key":"766_CR217","doi-asserted-by":"publisher","first-page":"2260","DOI":"10.3389\/fimmu.2018.02260","volume":"9","author":"S Chauvet","year":"2018","unstructured":"Chauvet, S. et al. Both monoclonal and polyclonal immunoglobulin contingents mediate complement activation in monoclonal gammopathy associated-C3 glomerulopathy. Front. Immunol. 9, 2260 (2018).","journal-title":"Front. Immunol."},{"key":"766_CR218","doi-asserted-by":"publisher","first-page":"7926","DOI":"10.1073\/pnas.1820892116","volume":"116","author":"A Schubart","year":"2019","unstructured":"Schubart, A. et al. Small-molecule factor B inhibitor for the treatment of complement-mediated diseases. Proc. Natl Acad. Sci. USA 116, 7926\u20137931 (2019).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"766_CR219","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.molimm.2019.07.030","volume":"114","author":"WM Zelek","year":"2019","unstructured":"Zelek, W. M., Xie, L., Morgan, B. P. & Harris, C. L. Compendium of current complement therapeutics. Mol. Immunol. 114, 341\u2013352 (2019).","journal-title":"Mol. Immunol."}],"container-title":["Nature Reviews Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41581-023-00766-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41581-023-00766-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41581-023-00766-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,15]],"date-time":"2023-11-15T12:04:55Z","timestamp":1700049895000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41581-023-00766-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,21]]},"references-count":219,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["766"],"URL":"https:\/\/doi.org\/10.1038\/s41581-023-00766-1","relation":{},"ISSN":["1759-5061","1759-507X"],"issn-type":[{"value":"1759-5061","type":"print"},{"value":"1759-507X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,21]]},"assertion":[{"value":"22 August 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 September 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"J.M.T. is a consultant for Q32 Bio, Inc., which is a company developing complement inhibitors. He holds stock and will receive royalty income from Q32 Bio, Inc. He co-founded and holds stock in Compsit3, a company developing complement diagnostics. V.P. declares no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}